Tetra Bio-Pharma Inc. (TBP.TO)

Toronto - Toronto Real Time Price. Currency in CAD

Add to watchlist

0.1600+0.0050 (+3.23%)

At close: 3:57PM EST

Full screen

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

View all chart patterns

Performance Outlook

Previous Close	0.1550
Open	0.1600
Bid	0.1550 x N/A
Ask	0.1600 x N/A
Day's Range	0.1450 - 0.1600
52 Week Range	0.1350 - 0.3700
Volume	3,527,244
Avg. Volume	1,536,329

Market Cap	57.355M
Beta (5Y Monthly)	1.93
PE Ratio (TTM)	N/A
EPS (TTM)	-0.1030
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

N/A

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

ACCESSWIRE
Tetra Bio-Pharma to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
OTTAWA, ON / ACCESSWIRE / March 3, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company")(TSX:TBP)(OTCQB:TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development announces that CEO Dr.
- Sonoma Pharmaceuticals to Present at Upcoming Spring Virtual Investor Conferences
  Business Wire
- Venus Concept Inc. to Present at the H.C. Wainwright Annual Global LifeSciences Conference on March 9th
  GlobeNewswire
CNW Group
Tetra Bio-Pharma Announces Closing of Bought Deal Offering
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/OTTAWA, ON, March 2, 2021 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development, is pleased to announce it has closed its previously announced bought-deal public offering of units (the "Units") of the Company.
- MediPharm Labs Closes Previously Announced Bought Deal Equity Financing
  GlobeNewswire
- Advanced Merger Partners, Inc. Announces Closing of $287.5 Million Initial Public Offering
  Business Wire
ACCESSWIRE
Tetra Bio-Pharma To Monetize Its Dronabinol And Botanical Product Portfolios
Company signs LOI for Nordics and GermanyOTTAWA, ON / ACCESSWIRE / February 25, 2021 /Tetra Bio-Pharma Inc. ("Tetra" or the "Company")(TSX:TBP)(OTCQB:TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development announced the signing of a Letter of Intent with DanCann Pharma A/S (SS: DANCAN) for the exclusive distribution of Reduvo™ Adversa® and QIXLEEF™ in Denmark, Norway, Sweden, Finland, and Germany.